Clarity Pharmaceuticals Ltd
ASX:CU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Square Four Projects India Ltd
BSE:526532
|
IN |
Clarity Pharmaceuticals Ltd
Total Current Liabilities
Clarity Pharmaceuticals Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Current Liabilities
AU$10.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Current Liabilities
AU$11.4m
|
CAGR 3-Years
114%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Current Liabilities
AU$261m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Current Liabilities
AU$4.3m
|
CAGR 3-Years
37%
|
CAGR 5-Years
42%
|
CAGR 10-Years
6%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Total Current Liabilities
AU$24.2m
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Nyrada Inc
ASX:NYR
|
Total Current Liabilities
AU$545.6k
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
See Also
What is Clarity Pharmaceuticals Ltd's Total Current Liabilities?
Total Current Liabilities
10.4m
AUD
Based on the financial report for Jun 30, 2025, Clarity Pharmaceuticals Ltd's Total Current Liabilities amounts to 10.4m AUD.
What is Clarity Pharmaceuticals Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
61%
Over the last year, the Total Current Liabilities growth was 28%. The average annual Total Current Liabilities growth rates for Clarity Pharmaceuticals Ltd have been 11% over the past three years , 61% over the past five years .
